Evidence map›Paper›PMID 19374550›Full record

ReviewZebrafish2009

A primer for morpholino use in zebrafish.

Brent R Bill, Andrew M Petzold, Karl J Clark, Lisa A Schimmenti, Stephen C Ekker

Abstract readReview
In one paragraph

Review in Zebrafish, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 211 papers.

0numbers the graph read from it
0cells of the map it votes in
211citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

211 citing papers in PubMed.

  1. Chemically Evolved XNAzyme Platforms for Effective In Vivo Gene Regulation.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Protein turnover downstream of the Nipbl/CRL4 axis contributes to abnormal development in zebrafish embryos.Developmental dynamics : an official publication of the American Association of Anatomists · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. The Interaction Between theInternational journal of molecular sciences · 2025
    Article
  17. Article
  18. International journal of molecular sciences · 2024
    Article
  19. Review
  20. Article

151 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Brent R BillDepartment of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, Minnesota, USA.
Andrew M Petzold
Karl J Clark
Lisa A Schimmenti
Stephen C Ekker

Funding

Systematic Vertebrate Functional GenomicsR01GM063904 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI EKKER, STEPHEN CARL · 2001 to 2025
$10.7M
VISUAL NEUROSCIENCE TRAINING PROGRAMT32EY007133 · NEI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MCLOON, STEVEN C · 1991 to 2010
$2.0M
Systematic Vertebrate Functional GenomicsR56GM063904 · NIGMS · MAYO CLINIC ROCHESTER · PI EKKER, STEPHEN CARL · 2009 to 2010
$611k
NEI NIH HHS T32 EY007133NIGMS NIH HHS R01 GM063904NIGMS NIH HHS R56 GM063904
6 · The paper itself

Abstract

Morpholino oligonucleotides are the most common anti-sense "knockdown" technique used in zebrafish (Danio rerio). This review discusses common practices for the design, preparation, and deployment of morpholinos in this vertebrate model system. Off-targeting effects of morpholinos are discussed as well as method to minimize this potentially confounding variable via co-injection of a tP53-targeting morpholino. Finally, new uses of morpholinos are summarized and contextualized with respect to the complementary, DNA-based knockout technologies recently developed for zebrafish.

Indexed as

Gene Knockdown TechniquesAnimalsOligonucleotidesZebrafishOligonucleotides

Identifiers

PMID19374550
PMCPMC2776066

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.